Q-omics provides the consensus-scored ANKRD16 profile across patient tissues and cancer cell-line models. ANKRD16 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, ANKRD16 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, ANKRD16 RNA expression shows 19,688 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, KIRC, and ACC as cancer lineages where ANKRD16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD16 survival associations across molecular data types. ANKRD16 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD16 RNA expression–survival associations across cancer types. High ANKRD16 expression shows unfavorable associations in LIHC, UVM, ACC and KIRC, but favorable associations in LGG and PAAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for ANKRD16 RNA expression.
This table summarizes ANKRD16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ANKRD16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD16 shows lower tumor expression in THCA and higher tumor expression in KIRC, COAD, LIHC, LUAD and LUSC. The KIRC box plot shows higher ANKRD16 RNA expression in tumor versus normal tissue (log2 FC = +0.648, t-test p < 0.001).
This table shows molecular features associated with ANKRD16 in patient tissues and cancer cell lines. In patient samples, ANKRD16 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD16 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SKIN and SOFT_TISSUE.
